The Supreme Court has dismissed the plea against the 2014 notification seeking to regulate prices of 108 diabetic and cardiac drugs, reports CNBC-TV18.A whole list of listed companies could get affected by order.
In 2014, the National Pharmaceutical Pricing Authority (NPPA) came out with a notification where they sought to regulate the prices of non-scheduled drugs. It was an interesting move given how NPPA used its powers rarely. These powers allow NPPA to proceed with regulations of prices of drugs even for drugs that are not in the prescribed schedule provided there is an extraordinary situation.
Since these diseases were widespread and the market mechanism to provide cheap affordable drugs wasn’t there, there was a need for government agency to step in and regulate.
In July of 2014, they had passed this notification and given the widespread impact, companies like Sanofi,Cipla, Dr Reddy’s, Pzifer could be affected. They had taken recourse to legal remedy and had appealed to several high courts.
In September, the Mumbai HC had passed a scathing order by upholding the 2014 notification and it also gave a free hand to the NPPA to go ahead and proceed in terms recovery proceedings against pharmas. That order was challenged before the apex court. After a summary hearing, the apex hadn’t found any merit. The pharma companies had argued that the notification was arbitrary.
Watch video for more...
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.